> Motif Bio raised £2.7 million ($3.6 million). The sum is expected to see Motif through to the receipt of minutes from a meeting with the FDA that will determine the future of its antibiotic. Statement
> Exscientia set up a subsidiary in Japan. Daisuke Tanaka, who collaborated with Exscientia while at Sumitomo Dainippon Pharma, will lead the outpost. Release
> Nuformix dosed the first patient in a trial of its chemotherapy-induced nausea and vomiting drug. The trial is comparing the bioavailability of the drug to that of Merck’s Emend. Statement
> Evox Therapeutics received £1.5 million from Innovate UK to advance an exosome treatment for a urea cycle disorder. The money will support preclinical development. Release
> BioInvent and Transgene extended their collaboration. The pair are working on oncolytic viruses for the treatment of solid tumors. Statement
> Bali Muralidhar joined Abingworth as a partner. Muralidhar was previously senior partner at MVM Partners, where he was involved in investments in companies including Wilson Therapeutics. Release